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ABSTRACT
Brown tumours may occur secondary to 
hyperparathyroidism in patients with chronic renal 
failure (CRF). Diagnosing a spinal brown tumour 
causing cord compression requires a high index of 
suspicion. We report a 65-year-old woman, who 
had been on haemodialysis for CRF for over 10 
years, who presented with leg weakness and back 
pain over the thoracolumbar junction. She had a 
brown tumour at T8 causing subacute spinal cord 
compression. Ambulation was regained after surgical 
decompression and stabilisation. Adherence to 
the National Kidney Foundation guidelines in the 
management of patients with CRF may prevent renal 
osteodystrophy. Treatment of spinal brown tumour 
depends on the severity of the neurological deficit. 
Remineralisaton is expected after correction of the 
parathyroid level, thus negating the need for total 
excision of the parathyroid glands.
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INTRODUCTION
Patients with chronic renal failure (CRF) on long-
term haemodialysis are at risk of secondary 
hyperparathyroidism due to phosphate retention 
and lowered calcitriol levels. Brown tumours are 
uncommon sequelae in hyperparathyroidism.1 They are 
not neoplasms, but can grow considerably in size and 
compress vital structures,2 particularly in the mandible, 
maxilla, ribs, and pelvis. Incidence rates of 1.5 to 13% 
have been reported in patients with CRF.3 Vertebral 
brown tumours are rare and a high index of suspicion 
is required for early diagnosis and treatment. We report 
a case of brown tumour at T8 causing subacute spinal 
cord compression in a patient with CRF.
CASE REPORT
In 2006, a 65-year-old woman who had been on 
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haemodialysis for CRF for over 10 years presented 
with a 6-month history of back pain over the 
thoracolumbar junction. Her leg power had 
deteriorated considerably a week before presentation 
and she was unable to walk. She had sustained a 
wedge fracture of T12 about 20 years earlier and 
developed a kyphosis at the thoracolumbar junction. 
Physical examination revealed local tenderness over 
the gibbus. Her leg power was 3 out of 5 based on 
the Medical Research Council grading4 and the deep 
tendon reflexes were diminished. The plantar reflex 
was equivocal on the right and upgoing on the left. 
Sharp/blunt discrimination was intact, but vibration 
sense was reduced in the right leg. A rectal examination 
revealed lax anal tone and absent anal grip despite 
no complaint of bowel or urinary symptoms. Upper 
limb functions were normal.
 Radiographs showed marked wedging of T12, 
with mild collapse of T11, resulting in an acute 
kyphosis over the thoracolumbar junction (Fig. 1). 
No abnormalities were visible at T8 because this was 
obscured by lung shadows. A bone scan revealed 
no increased uptake over T8. Magnetic resonance 
imaging (MRI) showed cord compression at T8 but 
not at T12. A sagittal T2–short tau inversion recovery 
(STIR) image showed a hyperintense lesion at T8 (Fig. 
2a), whereas a transverse T1-weighted image showed 
an isointense lesion involving posterior elements of 
T8, causing spinal cord compression and displacing 
the cord to the right (Fig. 2b). There were folds of 
ligamentum flavum between the T9/T10 and T10/
T11 junctions. Computed tomographic (CT) scanning 
confirmed a lytic, expansile lesion at T8 arising from 
the left lamina and extending cephalad to abutt the 
posterior element of T7, with no obvious intra-lesional 
calcification (Fig. 3).
 Her creatinine level was 382 (normal range, 45–
82) µmol/l, calcium level adjusted for serum albumin 
was 2.27 (normal range, 2.24–2.63) mmol/l, phosphate 
Figure 1 (a) Anteroposterior and (b) lateral radiographs of 
the thoracic spine showing collapse of T11 and T12.
Figure 2 (a) Sagittal T2-weighted image showing a 
hyperintense lesion at T8 and hypertrophic ligamentum flavum 
at T9/T10 and T10/11. (b) Transverse T1-weighted image 
showing an isointense lesion involving posterior elements of 
T8, causing spinal cord compression and displacing the cord 
to the right.
Figure 3 (a) Axial and (b) sagittal sections of computed 
tomographic scans showing an expansile, lytic lesion in the 
left T8 lamina extending to about T7.
(a) (b) (a) (b)
(a) (b)
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level was 1.57 (normal range, 0.88–1.45) mmol/l, 
and alkaline phosphatase level was 378 (normal 
range, 54–140) u/l. Treatment for her CRF included 
haemodialysis 3 times a week, erythropoietin β, and 
alfacalcidol. Her white cell count was normal.
 A percutaneous CT-guided Tru-Cut needle biopsy 
of the posterior T8 vertebra revealed no malignancy 
but the presence of multinucleated giant cells on a 
background of hypervascular fibroblastic stroma 
(Fig. 4). The serum parathyroid hormone (PTH) level 
was markedly elevated (intact PTH immunoassay, 
93.2 pmol/l; normal range, 1.2–5.7 pmol/l). This 
confirmed the diagnosis of a brown tumour at T8.
 Surgical decompression was performed in view of 
pending paralysis. Severe cord compression secondary 
to the epidural tumour mass was noted from T7 to 
T8/9 disc level, with erosion of the left T7/8 facet 
joint and transverse processes. Decompression was 
achieved through a T7 and T8 laminectomy until the 
dura was seen and the left T7/8 facet joint was taken 
down, using a standard posterior midline approach. 
The tumour was debulked using an ultrasonic suction 
aspirator.5 The spine was fused with instrumentation 
from T6 to T10 using autogenous cancellous bone 
graft from the left ilium.
 The patient was prescribed a thoracolumbar 
orthosis for 4 months. Her motor power improved 
gradually to grade 4 after rehabilitation. Radiographs 
at 3 months showed no major collapse of T8 (Fig. 5). 
At the one-year follow-up, she could walk unaided 
for over 15 minutes. Her hyperparathyroidism was 
treated medically as she had undergone thyroidectomy 
20 years earlier, and the parathyroid scintigraphy was 
negative.
DISCUSSION
The overall incidence of brown tumours is greater 
in patients with primary than with secondary 
hyperparathyroidism.6 Nonetheless, more spinal 
brown tumours result from secondary than 
from primary hyperparathyroidism. Secondary 
hyperparathyroidism is due to compensatory 
hypersecretion of PTH and can thus be caused by any 
condition that chronically suppresses calcium levels.7 
The most common cause is chronic renal failure, 
followed by inadequate dietary intake of calcium and 
vitamin-D deficiency.7 In the later stages of secondary 
hyperparathyroidism, some patients develop 
tertiary hyperparathyroidism, with autonomous and 
excessive PTH secretion, despite hypercalcaemia.7
 Hyperparathyroidism causes loss of cortical 
bone and predisposes to microfractures and 
secondary haemorrhage, which leads to an influx 
of multinucleated macrophages and the ingrowth 
of reparative fibrous tissue, a reactive tissue mass 
known as a brown tumour forms and they may 
encroach upon other structures.8 The vascularity, 
haemorrhage, and haemosiderin deposition gives 
rise to the characteristic colour. Cystic degeneration 
is not uncommon.8 The pathophysiology of renal 
osteodystrophy and brown tumour is complex. The 
histopathology lacks a pathognomonic feature and 
the predominant pattern (whether osteomalacic or 
osteosclerotic, high- or low-turnover, or mixed) may 
be affected by a number of variables. The PTH level is 
almost always elevated; a greater level of elevation is 
Figure 4 Photomicrograph of the T8 lesion showing a 
cluster of multinucleated giant cells in fibroblastic stroma 
(H&E, x10).
Figure 5 Postoperative (a) anteroposterior and (b) lateral 
radiographs showing pedicle screw instrumentation from T6 
to T10, with no significant collapse of T8.
(a) (b)
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required to cause dynamic bone disease owing to PTH 
resistance.9 Several factors are known to contribute 
to adynamic bone diseases, including the use of 
high dialysate calcium concentration, large doses of 
calcium-containing phosphate binders, inappropriate 
use of active vitamin D sterols, peritoneal dialysis, and 
aluminium toxicity (owing to the use of aluminium-
based phosphate binders).9
 Symptomatic hyperparathyroidism usually 
presents with complaints described as painful bones, 
renal stones, abdominal groans, and psychic moans.1 
Most densitometry studies support the view that 
hyperparathyroidism leads to cortical bone catabolism 
and relative cancellous bone preservation.10
 Bone abnormalities and other changes associated 
with PTH excess are less severe in secondary than 
primary hyperparathyroidism.1 There have been 
8 cases of spinal brown tumour due to secondary 
hyperparathyroidism reported in patients with CRF 
on haemodialysis (Table).3,11–17 In one other case the 
patient had CRF but was not on haemodialysis, 
and there was a case in a patient with chronic 
pyelonephritis for over 20 years who was awaiting 
haemodialysis or transplantation. All but one of the 
patients were women, and the thoracic spine was 
most commonly involved. Only 2 patients were over 
60 years of age, possibly reflecting decreased bone 
remodelling with ageing. 
 Findings on imaging vary according to the 
modality used. On radiographs, it is difficult to define 
the margin of a brown tumour in the spine because of 
overlapping shadows, but in the peripheral skeleton 
these tumours are well defined, expansile with internal 
septations or with sclerosis in the later stages.18 
On bone scans, they are often hypervascular, with 
increased uptake in the immediate-blood-flow phase. 
In 3-phase bone scans, enhancement in all 3 phases 
indicates regional perfusion, osteoid formation, and 
mineralisation.19 In contrast, extremely aggressive 
tumours disrupting local blood supply or displacing 
bone marrow may produce cold lesions. The amount 
of tracer uptake in the delayed-blood-flow phase 
depends on the extent of the mineralisation front 
and intensity of osteitis fibrosa.20 In our patient, the 
negative bone scan suggests a lesion with limited 
osteoblastic activity. On MRI, our patient’s lesion 
was hyperintense on T2-weighted imaging, which is 
consistent with other reports.15
 A fast field echo would show the haemosiderin 
deposits of a brown tumour better, and gadolinium 
contrast would show enhancement of the lesion.21
 The differential diagnosis of a brown tumour 
includes a giant cell tumour and an aneurysmal bone 
cyst. In giant cell tumours, the stromal spindle cells 
are more swollen, and the osteoclastic multinucleated 
giant cells are more regularly distributed and tend 
not to appear in aggregates, without interstitial 
haemorrhage.6 Aneurysmal bone cysts have a slight 
preponderance in females and tend to affect patients 
aged 10 to 20 years, with multiloculated cysts with 
fluid levels seen on MRI.22 Cytological tests help 
differentiate malignant from benign lesions, but 
cannot confirm the diagnosis. Serum PTH levels 
are therefore paramount in both the diagnosis and 
monitoring of treatment for brown tumours.
 In patients with CRF, PTH levels are often 
elevated because of PTH resistance, and this may 
worsen with progression of renal failure. In patients 
with mild-to-moderate renal failure, PTH levels have 
been reported to range from 1.8 to 40.3 pmol/l.23 
Patients with CRF and spinal brown tumour have 
markedly elevated PTH levels, often more than 10 
times normal.6,9,23 Calcium and phosphate levels 
may be normal in secondary hyperparathyroidism.18 
Studies Sex/age 
(years)
Haemodialysis Spine segment involved Surgical decompression
Ericsson et al.,11 1978 F/47 Pending Cervico-thoracic junction Yes
Bohlman et al.,12 1986 F/69 No Thoracic No (patient died)
Pumar et al.,13 1990 F/24 Yes Thoracic Yes
Barlow and Archer,14 1993 F/31 Yes Cervical No (patient had radiculopathy)
Fineman et al.,15 1999 F/37 Yes Thoracic Yes
Azria et al.,16 2000 F/40 Yes Thoracic No (patient only had neck pain)
Masutani et al.,17 2001 F/39 Yes Thoracic Yes
Vandenbussche et al.,3 2004 F/34 Yes Thoracic Yes
Tarass et al.,7 2005 M/42 Yes Sacral Yes
Current case F/65 Yes Thoracic Yes
Table
Cases of spinal brown tumour caused by secondary hyperparathyroidism in patients with chronic kidney disease
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CONCLUSION
Regular monitoring of PTH levels and treatment 
according to K/QODI guidelines helps prevent 
brown tumours in patients with CRF. The diagnosis 
of brown tumour hinges on the finding of a giant cell 
lesion on biopsy and a markedly elevated serum PTH 
level. Treatment should include normalisation of the 
PTH level, either via medication or more rapidly 
through parathyroidectomy. Surgical decompression 
of the spinal cord is necessary in the presence of spinal 
brown tumour and a severe neurological deficit.
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